{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:33:03Z","timestamp":1794720783088,"version":"4.9.1"},"reference-count":226,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft","id":[{"id":"https:\/\/ror.org\/043j0f473","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there is currently no disease-modifying treatment to halt neuronal loss in PD. A major hurdle for developing and testing such curative therapies results from the fact that most DA neurons are already lost at the time of the clinical diagnosis, rendering them inaccessible to therapy. Understanding the early pathological changes that precede Lewy body pathology (LBP) and cell loss in PD will likely support the identification of novel diagnostic and therapeutic strategies and help to differentiate LBP-dependent and -independent alterations. Several previous studies identified such specific molecular and cellular changes that occur prior to the appearance of Lewy bodies (LBs) in DA neurons, but a concise map of such early disease events is currently missing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we conducted a literature review to identify and discuss the results of previous studies that investigated cases with incidental Lewy body disease (iLBD), a presumed pathological precursor of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Collectively, our review demonstrates numerous cellular and molecular neuropathological changes occurring prior to the appearance of LBs in DA neurons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our review provides the reader with a summary of early pathological events in PD that may support the identification of novel therapeutic and diagnostic targets and aid to the development of disease-modifying strategies in PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-023-00622-7","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T09:04:14Z","timestamp":1683882254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Neuropathology of incidental Lewy body &amp; prodromal Parkinson\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6101-0323","authenticated-orcid":false,"given":"Thomas","family":"Koeglsperger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja-Lotta","family":"Rumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Schlie\u00dfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L.","family":"Struebing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Herms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"622_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/mds.25844","volume":"29","author":"D Berg","year":"2014","unstructured":"Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson\u2019s disease. Mov Disord. 2014;29:454\u201362.","journal-title":"Mov Disord"},{"key":"622_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/mds.10115","volume":"17","author":"O Hornykiewicz","year":"2002","unstructured":"Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord. 2002;17:501\u20138.","journal-title":"Mov Disord"},{"key":"622_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/mds.25952","volume":"29","author":"AA Dijkstra","year":"2014","unstructured":"Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ, Bank NB, Rozemuller AJM, et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson\u2019s disease. Mov Disord. 2014;29:1244\u201351.","journal-title":"Mov Disord"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"622_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22:1099\u2013109.","journal-title":"Nat Neurosci"},{"key":"622_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin MC, Chartier-Harlin M-C, Kachergus J, Kachergus J, Roumier C, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet. 2004;364:1167\u20139.","journal-title":"Lancet"},{"key":"622_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138.","journal-title":"Nat Genet"},{"key":"622_CR8","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science (New York, NY). 1997;276:2045\u20137.","journal-title":"Science (New York, NY)"},{"key":"622_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000107702","volume":"4","author":"S Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A Prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis. 2007;4:424\u20137.","journal-title":"Neurodegener Dis"},{"key":"622_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet. 2014;46:989\u201393.","journal-title":"Nat Genet"},{"key":"622_CR11","first-page":"S73","volume":"7","author":"H Braak","year":"2017","unstructured":"Braak H, Tredici KD. neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff. J Park Dis. 2017;7:S73-87.","journal-title":"J Park Dis"},{"key":"622_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.242","volume-title":"100 years of Lewy pathology","author":"M Goedert","year":"2013","unstructured":"Goedert M, Spillantini MG, Tredici KD, Braak H. 100 years of Lewy pathology. 2013."},{"key":"622_CR13","first-page":"1","volume":"201","author":"H Braak","year":"2009","unstructured":"Braak H, Braak H, Tredici KD, Tredici KD. Neuroanatomy and pathology of sporadic Parkinson\u2019s disease. Adv Anat Embryol Cell Biol. 2009;201:1\u2013119.","journal-title":"Adv Anat Embryol Cell Biol"},{"key":"622_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00702-019-02028-6","volume":"126","author":"KA Jellinger","year":"2019","unstructured":"Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update\u2014I Hypokinetic-rigid movement disorders. J Neural Transm. 2019;126:933\u201395.","journal-title":"J Neural Transm"},{"key":"622_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2174\/1871527314666150317225659","volume":"14","author":"J Sian-Hulsmann","year":"2015","unstructured":"Sian-Hulsmann J, Monoranu C, Strobel S, Riederer P. Lewy bodies: a spectator or salient killer? Cns Neurol Disord Drug Targets. 2015;14:947\u201355.","journal-title":"Cns Neurol Disord Drug Targets"},{"key":"622_CR16","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1353-8020(11)70011-6","volume":"18","author":"WDJ van de Berg","year":"2012","unstructured":"van de Berg WDJ, Hepp DH, Dijkstra AA, Rozemuller JAM, Berendse HW, Foncke E. Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson\u2019s disease. Parkinsonism Relat D. 2012;18:S28-30.","journal-title":"Parkinsonism Relat D"},{"key":"622_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"622_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak H, Ghebremedhin E, R\u00fcb U, Bratzke H, Tredici KD. Stages in the development of Parkinson\u2019s disease-related pathology. Cell Tissue Res. 2004;318:121\u201334.","journal-title":"Cell Tissue Res"},{"key":"622_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117:613\u201334.","journal-title":"Acta Neuropathol"},{"key":"622_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"J-Y Li","year":"2008","unstructured":"Li J-Y, Li JY, Englund E, Englund E, Holton JL, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501\u20133.","journal-title":"Nat Med"},{"key":"622_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14:504\u20136.","journal-title":"Nat Med"},{"key":"622_CR22","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1084\/jem.20160368","volume":"213","author":"NL Rey","year":"2016","unstructured":"Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, et al. Widespread transneuronal propagation of \u03b1-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson\u2019s disease. J Exp Med. 2016;213:1759\u201378.","journal-title":"J Exp Med"},{"key":"622_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk KC, Kehm V, Carroll J, Zhang B, O\u2019Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (New York, NY). 2012;338:949\u201353.","journal-title":"Science (New York, NY)"},{"key":"622_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"W Peelaerts","year":"2015","unstructured":"Peelaerts W, Bousset L, der Perren AV, Moskalyuk A, Pulizzi R, Giugliano M, et al. \u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340\u20134.","journal-title":"Nature"},{"key":"622_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, et al. Prion-like spreading of pathological \u03b1-synuclein in brain. Brain. 2013;136:1128\u201338.","journal-title":"Brain"},{"key":"622_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens A, Dehay B, Bov\u00e9 J, Carballo-Carbajal I, Dovero S, P\u00e9rez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75:351\u201362.","journal-title":"Ann Neurol"},{"key":"622_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-017-0413-0","volume":"5","author":"A Shimozawa","year":"2017","unstructured":"Shimozawa A, Ono M, Takahara D, Tarutani A, Imura S, Masuda-Suzukake M, et al. Propagation of pathological \u03b1-synuclein in marmoset brain. Acta Neuropathol Commun. 2017;5:12.","journal-title":"Acta Neuropathol Commun"},{"key":"622_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1988;51:745\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"622_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-008-0406-y","volume":"116","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 2008;116:1\u201316.","journal-title":"Acta Neuropathol"},{"key":"622_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","volume":"115","author":"L Parkkinen","year":"2008","unstructured":"Parkkinen L, Pirttil\u00e4 T, Alafuzoff I. Applicability of current staging\/categorization of \u03b1-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399\u2013407.","journal-title":"Acta Neuropathol"},{"key":"622_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1212\/WNL.49.2.610","volume":"49","author":"O Ansorge","year":"1997","unstructured":"Ansorge O, Daniel SE, Pearce RK. Neuronal loss and plasticity in the supraoptic nucleus in Parkinson\u2019s disease. Neurology. 1997;49:610\u20133.","journal-title":"Neurology"},{"key":"622_CR32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/mds.10258","volume":"17","author":"V MacDonald","year":"2002","unstructured":"MacDonald V, Halliday GM. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson\u2019s disease. Mov Disord. 2002;17:1166\u201373.","journal-title":"Mov Disord"},{"key":"622_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/mds.20289","volume":"20","author":"KM Pedersen","year":"2005","unstructured":"Pedersen KM, Marner L, Pakkenberg H, Pakkenberg B. No global loss of neocortical neurons in Parkinson\u2019s disease: a quantitative stereological study. Mov Disord. 2005;20:164\u201371.","journal-title":"Mov Disord"},{"key":"622_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ana.410270405","volume":"27","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson\u2019s disease. Ann Neurol. 1990;27:373\u201385.","journal-title":"Ann Neurol"},{"key":"622_CR35","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/brain\/awm097","volume":"130","author":"TC Thannickal","year":"2007","unstructured":"Thannickal TC, Lai Y-Y, Siegel JM. Hypocretin (orexin) cell loss in Parkinson\u2019s disease. Brain. 2007;130:1586\u201395.","journal-title":"Brain"},{"key":"622_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mds.870080310","volume":"8","author":"HP Kremer","year":"1993","unstructured":"Kremer HP, Bots GT. Lewy bodies in the lateral hypothalamus: do they imply neuronal loss? Mov Disord. 1993;8:315\u201320.","journal-title":"Mov Disord"},{"key":"622_CR37","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1212\/WNL.0000000000002102","volume":"85","author":"D Iacono","year":"2015","unstructured":"Iacono D, Geraci-Erck M, Rabin ML, Adler CH, Serrano G, Beach TG, et al. Parkinson disease and incidental Lewy body disease: just a question of time? Neurology. 2015;85:1670\u20139.","journal-title":"Neurology"},{"key":"622_CR38","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord. 2017;32:1504\u201323.","journal-title":"Mov Disord"},{"key":"622_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","volume":"72","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE, Hazrati L-N, Fujioka S, Wszolek ZK, Dickson DW, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72:100\u20135.","journal-title":"JAMA Neurol"},{"key":"622_CR40","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamaneurol.2013.172","volume":"70","author":"KM Doherty","year":"2013","unstructured":"Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol. 2013;70:571\u20139.","journal-title":"JAMA Neurol"},{"key":"622_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","volume":"27","author":"K Wakabayashi","year":"2007","unstructured":"Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson\u2019s disease: molecules implicated in the formation and degradation of \u03b1-synuclein aggregates: molecular components of Lewy body. Neuropathology. 2007;27:494\u2013506.","journal-title":"Neuropathology"},{"key":"622_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0006-8993(97)00874-3","volume":"775","author":"MM Tompkins","year":"1997","unstructured":"Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res. 1997;775:24\u20139.","journal-title":"Brain Res"},{"key":"622_CR43","first-page":"267","volume":"148","author":"C Bergeron","year":"1996","unstructured":"Bergeron C, Petrunka C, Weyer L, Pollanen MS. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathology. 1996;148:267\u201372.","journal-title":"Am J Pathology"},{"key":"622_CR44","first-page":"728","volume":"149","author":"WD Hill","year":"1996","unstructured":"Hill WD. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathol. 1996;149:728\u20139.","journal-title":"Am J Pathol"},{"key":"622_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0306-4522(90)90389-L","volume":"38","author":"F Javoy-Agid","year":"1990","unstructured":"Javoy-Agid F, Hirsch EC, Dumas S, Duyckaerts C, Mallet J, Agid Y. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in parkinson\u2019s disease: An in situ hybridization study. Neuroscience. 1990;38:245\u201353.","journal-title":"Neuroscience"},{"key":"622_CR46","first-page":"373","volume":"6","author":"S Patt","year":"1991","unstructured":"Patt S, Gertz HJ, Gerhard L, Cerv\u00f3s-Navarro J. Pathological changes in dendrites of substantia nigra neurons in Parkinson\u2019s disease: a Golgi study. Histol Histopathol. 1991;6:373\u201380.","journal-title":"Histol Histopathol"},{"key":"622_CR47","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.53.9.2003","volume":"53","author":"T Gomez-Isla","year":"1999","unstructured":"Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology. 1999;53:2003\u20132003.","journal-title":"Neurology"},{"key":"622_CR48","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1212\/WNL.53.6.1284","volume":"53","author":"E Gomez-Tortosa","year":"1999","unstructured":"Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999;53:1284\u20131284.","journal-title":"Neurology"},{"key":"622_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila PM, Rinne JO, Helenius H, Dickson DW, R\u00f6ytt\u00e4 M, Mattila PM. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease. Acta Neuropathol. 2000;100:285\u201390.","journal-title":"Acta Neuropathol"},{"key":"622_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1212\/01.wnl.0000266626.64913.0f","volume":"69","author":"D Weisman","year":"2007","unstructured":"Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007;69:356\u20139.","journal-title":"Neurology"},{"key":"622_CR51","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/elps.201800316","volume":"39","author":"X Dong","year":"2018","unstructured":"Dong X, Mondello S, Kobeissy F, Talih F, Ferri R, Mechref Y. LC\u2013MS\/MS glycomics of idiopathic rapid eye movement sleep behavior disorder. Electrophoresis. 2018;39:3096\u2013103.","journal-title":"Electrophoresis"},{"key":"622_CR52","doi-asserted-by":"publisher","first-page":"e1710","DOI":"10.1212\/WNL.0000000000006439","volume":"91","author":"S Mondello","year":"2018","unstructured":"Mondello S, Kobeissy F, Mechref Y, Zhao J, Talih FR, Cosentino F, et al. Novel biomarker signatures for idiopathic REM sleep behavior disorder: a proteomic and system biology approach. Neurology. 2018;91:e1710\u20135.","journal-title":"Neurology"},{"key":"622_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s004010050454","volume":"91","author":"ML Schmidt","year":"1996","unstructured":"Schmidt ML, Martin JA, Lee VM-Y, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer\u2019s disease and Lewy body disorders. Acta Neuropathol. 1996;91:475\u201381.","journal-title":"Acta Neuropathol"},{"key":"622_CR54","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1212\/WNL.0b013e318278b6a7","volume":"79","author":"WJ Schulz-Schaeffer","year":"2012","unstructured":"Schulz-Schaeffer WJ. Neurodegeneration in Parkinson disease: Moving Lewy bodies out of focus. Neurology. 2012;79:2298\u20139.","journal-title":"Neurology"},{"key":"622_CR55","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1474-4422(04)00827-0","volume":"3","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004;3:496\u2013503.","journal-title":"Lancet Neurol"},{"key":"622_CR56","doi-asserted-by":"publisher","first-page":"104876","DOI":"10.1016\/j.nbd.2020.104876","volume":"141","author":"HA Lashuel","year":"2020","unstructured":"Lashuel HA. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Neurobiol Dis. 2020;141:104876.","journal-title":"Neurobiol Dis"},{"key":"622_CR57","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science. 2004;304:1158\u201360.","journal-title":"Science"},{"key":"622_CR58","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. New Engl J Medicine. 2009;361:1651\u201361.","journal-title":"New Engl J Medicine"},{"key":"622_CR59","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","volume":"140","author":"LA Robak","year":"2017","unstructured":"Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J, et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease. Brain. 2017;140:3191\u2013203.","journal-title":"Brain"},{"key":"622_CR60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Brown E, Hallett P, et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann Clin Transl Neur. 2015;2:433\u20138.","journal-title":"Ann Clin Transl Neur"},{"key":"622_CR61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/ars.2015.6307","volume":"23","author":"EM Rocha","year":"2015","unstructured":"Rocha EM, Smith GA, Park E, Cao H, Graham A-R, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Sign. 2015;23:550\u201364.","journal-title":"Antioxid Redox Sign"},{"key":"622_CR62","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1093\/brain\/awz191","volume":"142","author":"MMX Tan","year":"2019","unstructured":"Tan MMX, Malek N, Lawton MA, Hubbard L, Pittman AM, Joseph T, et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson\u2019s disease study. Brain. 2019;142:2828\u201344.","journal-title":"Brain"},{"issue":"126","key":"622_CR63","first-page":"423","volume":"2018","author":"KA Jellinger","year":"1996","unstructured":"Jellinger KA. Is Braak staging valid for all types of Parkinson\u2019s disease? J Neural Transm Vienna Austria. 1996;2018(126):423\u201331.","journal-title":"J Neural Transm Vienna Austria"},{"key":"622_CR64","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnen\/63.7.742","volume":"63","author":"Y Saito","year":"2004","unstructured":"Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, et al. Lewy body-related \u03b1-synucleinopathy in aging. J Neuropathol Exp Neurology. 2004;63:742\u20139.","journal-title":"J Neuropathol Exp Neurology"},{"key":"622_CR65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2990.2006.00727.x","volume":"32","author":"A Bloch","year":"2006","unstructured":"Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006;32:284\u201395.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"622_CR66","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1016\/S1353-8020(11)70063-3","volume":"18","author":"JN Caviness","year":"2012","unstructured":"Caviness JN. Presymptomatic Parkinson\u2019s disease: the Arizona experience. Parkinsonism Relat D. 2012;18:S203\u20136.","journal-title":"Parkinsonism Relat D"},{"key":"622_CR67","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/mds.22971","volume":"25","author":"CH Adler","year":"2010","unstructured":"Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Movement Disord. 2010;25:642\u20136.","journal-title":"Movement Disord"},{"key":"622_CR68","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.parkreldis.2014.08.006","volume":"20","author":"E Driver-Dunckley","year":"2014","unstructured":"Driver-Dunckley E, Adler CH, Hentz JG, Dugger BN, Shill HA, Caviness JN, et al. Olfactory dysfunction in incidental Lewy body disease and Parkinson\u2019s disease. Parkinsonism Relat D. 2014;20:1260\u20132.","journal-title":"Parkinsonism Relat D"},{"key":"622_CR69","doi-asserted-by":"publisher","unstructured":"Adler CH, Dugger BN, Hentz JG, Hinni ML, Lott DG, Driver-Dunckley E, et al. Peripheral synucleinopathy in early Parkinson\u2019s disease: Submandibular gland needle biopsy findings.\u00a0Mov Disord. 2017;32(5):722-723. https:\/\/doi.org\/10.1002\/mds.27044. PMID: 28513078.","DOI":"10.1002\/mds.27044"},{"key":"622_CR70","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-004-0138-7","volume":"111","author":"KA Jellinger","year":"2004","unstructured":"Jellinger KA. Lewy body-related\u202f?-synucleinopathy in the aged human brain. J Neural Transm. 2004;111:1219\u201335.","journal-title":"J Neural Transm"},{"key":"622_CR71","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00401-008-0345-7","volume":"115","author":"DW Dickson","year":"2008","unstructured":"Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson\u2019s disease. Acta Neuropathol. 2008;115:437\u201344.","journal-title":"Acta Neuropathol"},{"key":"622_CR72","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard S, Verny M, Bonnet A-M, Beinis J-Y, Gallinari C, Meaume S, et al. Motor score of the unified parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol Chicago. 2006;63:584\u20138.","journal-title":"Arch Neurol Chicago"},{"key":"622_CR73","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136:2419\u201331.","journal-title":"Brain"},{"key":"622_CR74","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ana.25179","volume":"83","author":"Y Chu","year":"2018","unstructured":"Chu Y, Buchman AS, Olanow CW, Kordower JH. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018;83:562\u201374.","journal-title":"Ann Neurol"},{"key":"622_CR75","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing, and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991;114:2283\u2013301.","journal-title":"Brain"},{"issue":"Pt 8","key":"622_CR76","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain. 1999;122(Pt 8):1437\u201348.","journal-title":"Brain"},{"key":"622_CR77","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-011-0641-6","volume":"118","author":"GM Halliday","year":"2011","unstructured":"Halliday GM, Song YJC, Harding AJ. Striatal \u03b2-amyloid in dementia with Lewy bodies but not Parkinson\u2019s disease. J Neural Trans (Vienna, Austria: 1996). 2011;118:713\u20139.","journal-title":"J Neural Trans (Vienna, Austria: 1996)"},{"key":"622_CR78","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1001\/archneur.65.8.1074","volume":"65","author":"A DelleDonne","year":"2008","unstructured":"DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol. 2008;65:1074\u201380.","journal-title":"Arch Neurol"},{"key":"622_CR79","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","volume":"79","author":"JM Milber","year":"2012","unstructured":"Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology. 2012;79:2307\u201314.","journal-title":"Neurology"},{"key":"622_CR80","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.bbadis.2008.07.006","volume":"1792","author":"KA Jellinger","year":"2009","unstructured":"Jellinger KA. A critical evaluation of current staging of \u03b1-synuclein pathology in Lewy body disorders. BBA Mol Basis Dis. 2009;1792:730\u201340.","journal-title":"BBA Mol Basis Dis"},{"key":"622_CR81","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/mds.25825","volume":"29","author":"A Iranzo","year":"2014","unstructured":"Iranzo A, Gelpi E, Tolosa E, Molinuevo JL, Serradell M, Gaig C, et al. Neuropathology of prodromal Lewy body disease. Mov Disord. 2014;29:410\u20135.","journal-title":"Mov Disord"},{"key":"622_CR82","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00401-007-0313-7","volume":"115","author":"TG Beach","year":"2008","unstructured":"Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 2008;115:445\u201351.","journal-title":"Acta Neuropathol"},{"key":"622_CR83","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.neurobiolaging.2006.10.022","volume":"29","author":"E Dalf\u00f3","year":"2008","unstructured":"Dalf\u00f3 E, Ferrer I. Early \u03b1-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol Aging. 2008;29:408\u201317.","journal-title":"Neurobiol Aging"},{"key":"622_CR84","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00702-010-0482-8","volume":"118","author":"I Ferrer","year":"2011","unstructured":"Ferrer I, Martinez A, Blanco R, Dalf\u00f3 E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna, Austria: 1996). 2011;118:821\u201339.","journal-title":"J Neural Transm (Vienna, Austria: 1996)"},{"key":"622_CR85","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.parkreldis.2006.10.002","volume":"13","author":"D Koziorowski","year":"2007","unstructured":"Koziorowski D, Friedman A, Arosio P, Santambrogio P, Dziewulska D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson\u2019s disease and incidental Lewy body compared to control. Parkinsonism Relat D. 2007;13:214\u20138.","journal-title":"Parkinsonism Relat D"},{"issue":"10","key":"622_CR86","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41419-021-04138-0","volume":"12","author":"Q Tang","year":"2021","unstructured":"Tang Q, Gao P, Arzberger T, H\u00f6llerhage M, Herms J, H\u00f6glinger G, et al. Alpha-Synuclein defects autophagy by impairing SNAP29-mediated autophagosome-lysosome fusion. Cell Death Dis. 2021;12(10):854.","journal-title":"Cell Death Dis"},{"key":"622_CR87","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","volume":"62","author":"E Kuusisto","year":"2003","unstructured":"Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy Bodies: Dissimilar Incorporation of \u03b1-Synuclein, Ubiquitin, and p62. J Neuropathol Exp Neurol. 2003;62:1241\u201353.","journal-title":"J Neuropathol Exp Neurol"},{"key":"622_CR88","first-page":"90","volume":"2","author":"KJ Doorn","year":"2014","unstructured":"Doorn KJ, Moors T, Drukarch B, van de Berg WD, Lucassen PJ, van Dam A-M. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson\u2019s disease patients. Acta Neuropathol Commun. 2014;2:90.","journal-title":"Acta Neuropathol Commun"},{"key":"622_CR89","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00702-011-0684-8","volume":"119","author":"BD Bradaric","year":"2012","unstructured":"Bradaric BD, Patel A, Schneider JA, Carvey PM, Hendey B. Evidence for angiogenesis in Parkinson\u2019s disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm. 2012;119:59\u201371.","journal-title":"J Neural Transm"},{"key":"622_CR90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12031-015-0576-8","volume":"57","author":"MJ Hurley","year":"2015","unstructured":"Hurley MJ, Durrenberger PF, Gentleman SM, Walls AF, Dexter DT. Altered expression of brain proteinase-activated receptor-2, trypsin-2 and serpin proteinase inhibitors in Parkinson\u2019s disease. J Mol Neurosci. 2015;57:48\u201362.","journal-title":"J Mol Neurosci"},{"key":"622_CR91","first-page":"507","volume":"9","author":"DG Walker","year":"2016","unstructured":"Walker DG, Lue L-F, Serrano G, Adler CH, Caviness JN, Sue LI, et al. Altered expression patterns of inflammation-associated and trophic molecules in substantia nigra and striatum brain samples from Parkinson\u2019s disease, incidental Lewy body disease and normal control cases. Front Neurosci Switz. 2016;9:507.","journal-title":"Front Neurosci Switz"},{"key":"622_CR92","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira J, Torra A, Vila M, Bov\u00e9 J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain. 2020;143:3717\u201333.","journal-title":"Brain"},{"key":"622_CR93","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ana.410260409","volume":"26","author":"D Scherman","year":"1989","unstructured":"Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in parkinson\u2019s disease: role of aging. Ann Neurol. 1989;26:551\u20137.","journal-title":"Ann Neurol"},{"key":"622_CR94","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0022-510X(97)00100-7","volume":"151","author":"SY Ma","year":"1997","unstructured":"Ma SY, R\u00f6ytt\u00e4 M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson\u2019s disease using disector counts. J Neurol Sci. 1997;151:83\u20137.","journal-title":"J Neurol Sci"},{"key":"622_CR95","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-010-0711-0","volume":"120","author":"WJ Schulz-Schaeffer","year":"2010","unstructured":"Schulz-Schaeffer WJ. The synaptic pathology of \u03b1-synuclein aggregation in dementia with Lewy bodies, Parkinson\u2019s disease and Parkinson\u2019s disease dementia. Acta Neuropathol. 2010;120:131\u201343.","journal-title":"Acta Neuropathol"},{"key":"622_CR96","doi-asserted-by":"publisher","first-page":"e0128651","DOI":"10.1371\/journal.pone.0128651","volume":"10","author":"AA Dijkstra","year":"2015","unstructured":"Dijkstra AA, Ingrassia A, de Menezes RX, van Kesteren RE, Rozemuller AJM, Heutink P, et al. Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson\u2019s disease. PLoS One. 2015;10:e0128651.","journal-title":"PLoS One"},{"key":"622_CR97","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/ana.23568","volume":"71","author":"MT Lin","year":"2012","unstructured":"Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, et al. Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Ann Neurol. 2012;71:850\u20134.","journal-title":"Ann Neurol"},{"key":"622_CR98","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41588-020-0610-9","volume":"52","author":"J Bryois","year":"2020","unstructured":"Bryois J, Skene NG, Hansen TF, Kogelman LJA, Watson HJ, Liu Z, et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson\u2019s disease. Nat Genet. 2020;52:482\u201393.","journal-title":"Nat Genet"},{"key":"622_CR99","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00401-021-02343-x","volume":"142","author":"R Feleke","year":"2021","unstructured":"Feleke R, Reynolds RH, Smith AM, Tilley B, Taliun SAG, Hardy J, et al. Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases. Acta Neuropathol. 2021;142:449\u201374.","journal-title":"Acta Neuropathol"},{"key":"622_CR100","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bpa.12511","volume":"28","author":"G Santpere","year":"2017","unstructured":"Santpere G, Garcia-Esparcia P, Andres-Benito P, Lorente-Galdos B, Navarro A, Ferrer I. Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies: transcriptional network analysis. Brain Pathol. 2017;28:315\u201333.","journal-title":"Brain Pathol"},{"key":"622_CR101","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.ajpath.2011.07.021","volume":"179","author":"MMM Wilhelmus","year":"2011","unstructured":"Wilhelmus MMM, Bol JGJM, Haastert ESV, Rozemuller AJM, Bu G, Drukarch B, et al. Apolipoprotein E and LRP1 increase early in Parkinson\u2019s disease pathogenesis. Am J Pathol. 2011;179:2152\u20136.","journal-title":"Am J Pathol"},{"key":"622_CR102","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/brain\/119.3.823","volume":"119","author":"A Fernandez","year":"1996","unstructured":"Fernandez A, de Ceballos ML, Rose S, Jenner P, Marsden CD. Alterations in peptide levels in Parkinson\u2019s disease and incidental Lewy body disease. Brain. 1996;119:823\u201330.","journal-title":"Brain"},{"key":"622_CR103","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1002\/ana.410320714","volume":"32","author":"P Jenner","year":"1992","unstructured":"Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD, Group TRKAQPDR. Oxidative stress as a cause of nigral cell death in Parkinson\u2019s disease and incidental lewy body disease. Ann Neurol. 1992;32:S82-7.","journal-title":"Ann Neurol"},{"key":"622_CR104","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1021\/acs.jproteome.1c00219","volume":"20","author":"H Wilkinson","year":"2021","unstructured":"Wilkinson H, Thomsson KA, Rebelo AL, Hilliard M, Pandit A, Rudd PM, et al. The O-Glycome of human nigrostriatal tissue and its alteration in Parkinson\u2019s disease. J Proteome Res. 2021;20:3913\u201324.","journal-title":"J Proteome Res"},{"key":"622_CR105","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/BF01291884","volume":"104","author":"RKB Pearce","year":"1997","unstructured":"Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson\u2019s disease. J Neural Transm. 1997;104:661\u201377.","journal-title":"J Neural Transm"},{"key":"622_CR106","doi-asserted-by":"publisher","first-page":"161S","DOI":"10.1212\/WNL.47.6_Suppl_3.161S","volume":"47","author":"P Jenner","year":"1996","unstructured":"Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson\u2019s disease. Neurology. 1996;47:161S-170S.","journal-title":"Neurology"},{"key":"622_CR107","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-019-02099-5","volume":"139","author":"Y Tan","year":"2019","unstructured":"Tan Y, Sgobio C, Arzberger T, Machleid F, Tang Q, Findeis E, et al. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson\u2019s disease. Acta Neuropathol. 2019;139:319\u201345.","journal-title":"Acta Neuropathol"},{"key":"622_CR108","doi-asserted-by":"crossref","unstructured":"Beach TG, Adler CH, Sue LI, Shill HA, Driver-Dunckley E, Mehta SH, et al. Vagus nerve and stomach synucleinopathy in Parkinson\u2019s disease, incidental lewy body disease, and normal elderly subjects: evidence against the \u201cBody-First\u201d hypothesis. J Park Dis. 2021:1\u201311.","DOI":"10.1101\/2020.09.29.20204248"},{"key":"622_CR109","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1002\/mds.21560","volume":"22","author":"RD Abbott","year":"2007","unstructured":"Abbott RD, Ross GW, Petrovitch H, Tanner CM, Davis DG, Masaki KH, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Movement Disord. 2007;22:1581\u20136.","journal-title":"Movement Disord"},{"key":"622_CR110","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00401-010-0665-2","volume":"119","author":"KD Tredici","year":"2010","unstructured":"Tredici KD, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson\u2019s disease. Acta Neuropathol. 2010;119:703\u201313.","journal-title":"Acta Neuropathol"},{"key":"622_CR111","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00401-009-0596-y","volume":"118","author":"E Ghebremedhin","year":"2009","unstructured":"Ghebremedhin E, Tredici KD, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson\u2019s disease: an anatomical study. Acta Neuropathol. 2009;118:777.","journal-title":"Acta Neuropathol"},{"key":"622_CR112","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.pneurobio.2020.101919","volume":"199","author":"JL Labandeira-Garcia","year":"2021","unstructured":"Labandeira-Garcia JL, Valenzuela R, Costa-Besada MA, Villar-Cheda B, Rodriguez-Perez AI. The intracellular renin-angiotensin system: friend or foe. Some light from the dopaminergic neurons. Prog Neurobiol. 2021;199:101919.","journal-title":"Prog Neurobiol."},{"key":"622_CR113","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pharmthera.2006.10.001","volume":"113","author":"C Oro","year":"2007","unstructured":"Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Therapeut. 2007;113:210\u201326.","journal-title":"Pharmacol Therapeut"},{"key":"622_CR114","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2022.04.029","volume":"135","author":"H-C Lin","year":"2022","unstructured":"Lin H-C, Tseng Y-F, Shen A-L, Chao JC-J, Hsu C-Y, Lin H-L. Association of angiotensin receptor blockers with Incident Parkinson disease in patients with hypertension: a retrospective cohort study. Am J Medicine. 2022;135:1001\u20137.","journal-title":"Am J Medicine"},{"key":"622_CR115","doi-asserted-by":"publisher","first-page":"837890","DOI":"10.3389\/fphar.2022.837890","volume":"13","author":"Y Jo","year":"2022","unstructured":"Jo Y, Kim S, Ye BS, Lee E, Yu YM. Protective Effect of Renin-Angiotensin system inhibitors on Parkinson\u2019s disease: a nationwide cohort study. Front Pharmacol. 2022;13:837890.","journal-title":"Front Pharmacol"},{"key":"622_CR116","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.3390\/ijms24065914","volume":"24","author":"G Forloni","year":"2023","unstructured":"Forloni G. Alpha Synuclein: Neurodegeneration and Inflammation. Int J Mol Sci. 2023;24:5914.","journal-title":"Int J Mol Sci"},{"key":"622_CR117","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1326-7-42","volume":"7","author":"KM Danzer","year":"2012","unstructured":"Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012;7:42.","journal-title":"Mol Neurodegener"},{"key":"622_CR118","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease. Acta Neuropathol Commun. 2022;10:133.","journal-title":"Acta Neuropathol Commun"},{"key":"622_CR119","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.nbd.2020.105086","volume":"146","author":"ST Kumar","year":"2020","unstructured":"Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific \u03b1-synuclein antibodies? Characterization and validation of 16 \u03b1-synuclein conformation-specific antibodies using well-characterized preparations of \u03b1-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis. 2020;146:105086.","journal-title":"Neurobiol Dis"},{"key":"622_CR120","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1474-4422(17)30173-4","volume":"16","author":"MG Stokholm","year":"2017","unstructured":"Stokholm MG, Iranzo A, \u00d8stergaard K, Serradell M, Otto M, Svendsen KB, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16:789\u201396.","journal-title":"Lancet Neurol"},{"key":"622_CR121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12974-018-1171-z","volume":"15","author":"MF Duffy","year":"2018","unstructured":"Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Luk KC, Tansey MG, et al. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflamm. 2018;15:129.","journal-title":"J Neuroinflamm"},{"key":"622_CR122","doi-asserted-by":"publisher","first-page":"e029740","DOI":"10.1136\/bmjopen-2019-029740","volume":"9","author":"CB Carroll","year":"2019","unstructured":"Carroll CB, Webb D, Stevens KN, Vickery J, Eyre V, Ball S, et al. Simvastatin as a neuroprotective treatment for Parkinson\u2019s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study. BMJ Open. 2019;9:e029740.","journal-title":"BMJ Open"},{"key":"622_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","volume":"1037","author":"ML Selley","year":"2005","unstructured":"Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005;1037:1\u20136.","journal-title":"Brain Res"},{"key":"622_CR124","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","volume":"29","author":"A Ghosh","year":"2009","unstructured":"Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson\u2019s disease. J Neurosci. 2009;29:13543\u201356.","journal-title":"J Neurosci"},{"key":"622_CR125","unstructured":"The PD-STAT\/Simvastatin study results. Available from: https:\/\/cureparkinsons.org.uk\/2020\/09\/post-alternative-layout-2-without-image-2\/."},{"key":"622_CR126","doi-asserted-by":"publisher","first-page":"e040527","DOI":"10.1136\/bmjopen-2020-040527","volume":"10","author":"JC Greenland","year":"2020","unstructured":"Greenland JC, Cutting E, Kadyan S, Bond S, Chhabra A, Williams-Gray CH. Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 2020;10:e040527.","journal-title":"BMJ Open"},{"key":"622_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.957705","volume":"14","author":"Q Su","year":"2022","unstructured":"Su Q, Ng WL, Goh SY, Gulam MY, Wang L-F, Tan E-K, et al. Targeting the inflammasome in Parkinson\u2019s disease. Front Aging Neurosci. 2022;14: 957705.","journal-title":"Front Aging Neurosci"},{"key":"622_CR128","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","volume":"88","author":"CR Overk","year":"2014","unstructured":"Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease. Biochem Pharmacol. 2014;88:508\u201316.","journal-title":"Biochem Pharmacol"},{"key":"622_CR129","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1006\/exnr.1998.7008","volume":"156","author":"GW Miller","year":"1999","unstructured":"Miller GW, Erickson JD, Perez JT, Penland SN, Mash DC, Rye DB, et al. Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson\u2019s Disease. Exp Neurol. 1999;156:138\u201348.","journal-title":"Exp Neurol"},{"key":"622_CR130","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","volume":"27","author":"ML Kramer","year":"2007","unstructured":"Kramer ML, Schulz-Schaeffer WJ. Presynaptic -synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405\u201310.","journal-title":"J Neurosci"},{"key":"622_CR131","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","volume":"246","author":"RE Burke","year":"2012","unstructured":"Burke RE, O\u2019Malley K. Axon degeneration in Parkinson\u2019s disease. Exp Neurol. 2012;246:72\u201383.","journal-title":"Exp Neurol"},{"key":"622_CR132","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"H-C Cheng","year":"2010","unstructured":"Cheng H-C, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715\u201325.","journal-title":"Ann Neurol"},{"issue":"18","key":"622_CR133","doi-asserted-by":"publisher","first-page":"e98960","DOI":"10.15252\/embj.201898960","volume":"37","author":"S-F Soukup","year":"2018","unstructured":"Soukup S-F, Vanhauwaert R, Verstreken P. Parkinson\u2019s disease: convergence on synaptic homeostasis. Embo J. 2018;37(18):e98960.","journal-title":"Embo J."},{"key":"622_CR134","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tins.2018.11.001","volume":"42","author":"M Nguyen","year":"2018","unstructured":"Nguyen M, Wong YC, Ysselstein D, Severino A, Krainc D. Synaptic, mitochondrial, and lysosomal dysfunction in Parkinson\u2019s disease. Trends Neurosci. 2018;42:140\u20139.","journal-title":"Trends Neurosci"},{"key":"622_CR135","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainres.2012.04.014","volume":"1476","author":"A Bellucci","year":"2012","unstructured":"Bellucci A, Zaltieri M, Navarria L, Grigoletto J, Missale C, Spano P. From \u03b1-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson\u2019s disease. Brain Res. 2012;1476:183\u2013202.","journal-title":"Brain Res"},{"key":"622_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2009.06.008","volume":"204","author":"S Nikolaus","year":"2009","unstructured":"Nikolaus S, Antke C, M\u00fcller H-W. In vivo imaging of synaptic function in the central nervous system. Behav Brain Res. 2009;204:1\u201331.","journal-title":"Behav Brain Res"},{"key":"622_CR137","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1533317507310565","volume":"23","author":"GJ Revuelta","year":"2008","unstructured":"Revuelta GJ, Rosso A, Lippa CF. Neuritic Pathology as a Correlate of Synaptic Loss in Dementia With Lewy Bodies. Am J Alzheimer\u2019s Dis Other Dementiasr. 2008;23:97\u2013102.","journal-title":"Am J Alzheimer\u2019s Dis Other Dementiasr"},{"key":"622_CR138","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0006-8993(88)90124-2","volume":"455","author":"TH McNeill","year":"1988","unstructured":"McNeill TH, Brown SA, Rafols JA, Shoulson I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson\u2019s disease. Brain Res. 1988;455:148\u201352.","journal-title":"Brain Res"},{"key":"622_CR139","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1212\/01.WNL.0000150591.33787.A4","volume":"64","author":"S Zaja-Milatovic","year":"2005","unstructured":"Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology. 2005;64:545\u20137.","journal-title":"Neurology"},{"key":"622_CR140","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1471-4159.2009.06350.x","volume":"111","author":"T Kitada","year":"2009","unstructured":"Kitada T, Tong Y, Gautier CA, Shen J. Absence of nigral degeneration in aged parkin\/DJ-1\/PINK1 triple knockout mice. J Neurochem. 2009;111:696\u2013702.","journal-title":"J Neurochem"},{"key":"622_CR141","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1093\/brain\/awh150","volume":"127","author":"C Scherfler","year":"2004","unstructured":"Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004;127:1332\u201342.","journal-title":"Brain"},{"key":"622_CR142","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2014.04.021","volume":"68","author":"J-S Chou","year":"2014","unstructured":"Chou J-S, Chen C-Y, Chen Y-L, Weng Y-H, Yeh T-H, Lu C-S, et al. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol Dis. 2014;68:190\u20139.","journal-title":"Neurobiol Dis"},{"key":"622_CR143","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/hmg\/ddu543","volume":"24","author":"DA Beccano-Kelly","year":"2014","unstructured":"Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, et al. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet. 2014;24:1336\u201349.","journal-title":"Hum Mol Genet"},{"key":"622_CR144","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.25724","volume":"29","author":"G Madeo","year":"2013","unstructured":"Madeo G, Schirinzi T, Martella G, Latagliata EC, Puglisi F, Shen J, et al. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity: synaptic plasticity in Pink1 +\/\u2212 Mice. Movement Disord. 2013;29:41\u201353.","journal-title":"Movement Disord"},{"key":"622_CR145","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ajhg.2014.10.015","volume":"95","author":"GR Wilson","year":"2014","unstructured":"Wilson GR, Sim JCH, McLean C, Giannandrea M, Galea CA, Riseley JR, et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with \u03b1-synuclein pathology. Am J Hum Genetics. 2014;95:729\u201335.","journal-title":"Am J Hum Genetics"},{"key":"622_CR146","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-1331.2007.01853.x","volume":"14","author":"G Linazasoro","year":"2007","unstructured":"Linazasoro G. Classical Parkinson disease versus Parkinson complex\u202f? Reflections against staging and in favour of heterogeneity. Eur J Neurol. 2007;14:721\u20138.","journal-title":"Eur J Neurol"},{"key":"622_CR147","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tins.2014.12.009","volume":"38","author":"BHM Hunn","year":"2015","unstructured":"Hunn BHM, Cragg SJ, Bolam JP, Spillantini M-G, Wade-Martins R. Impaired intracellular trafficking defines early Parkinson\u2019s disease. Trends Neurosci. 2015;38:178\u201388.","journal-title":"Trends Neurosci"},{"key":"622_CR148","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1371\/journal.pgen.0030098","volume":"3","author":"TG Lesnick","year":"2007","unstructured":"Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, de Andrade M, et al. A Genomic pathway approach to a complex disease: axon guidance and Parkinson disease. Plos Genet. 2007;3:e98.","journal-title":"Plos Genet"},{"key":"622_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-005-0020-2","volume":"7","author":"LB Moran","year":"2006","unstructured":"Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RKB, Graeber MB. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson\u2019s disease. Neurogenetics. 2006;7:1\u201311.","journal-title":"Neurogenetics"},{"key":"622_CR150","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jnr.21904","volume":"87","author":"A G\u00f3mez","year":"2009","unstructured":"G\u00f3mez A, Ferrer I. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. J Neurosci Res. 2009;87:1002\u201313.","journal-title":"J Neurosci Res"},{"key":"622_CR151","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuron.2015.06.017","volume":"87","author":"A Contractor","year":"2015","unstructured":"Contractor A, Klyachko VA, Portera-Cailliau C. Altered neuronal and circuit excitability in fragile X syndrome. Neuron. 2015;87:699\u2013715.","journal-title":"Neuron"},{"key":"622_CR152","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","volume":"22","author":"JD Richter","year":"2021","unstructured":"Richter JD, Zhao X. The molecular biology of FMRP: new insights into fragile X syndrome. Nat Rev Neurosci. 2021;22:209\u201322.","journal-title":"Nat Rev Neurosci"},{"key":"622_CR153","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jns.2011.06.003","volume":"310","author":"KD Tredici","year":"2011","unstructured":"Tredici KD, Duda JE. Peripheral Lewy body pathology in Parkinson\u2019s disease and incidental Lewy body disease: four cases. J Neurol Sci. 2011;310:100\u20136.","journal-title":"J Neurol Sci"},{"key":"622_CR154","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/WNL.52.6.1269","volume":"52","author":"K Iwanaga","year":"1999","unstructured":"Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, et al. Lewy body-type degeneration in cardiac plexus in Parkinson\u2019s and incidental Lewy body diseases. Neurology. 1999;52:1269\u20131269.","journal-title":"Neurology"},{"key":"622_CR155","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1440-1789.2011.01211.x","volume":"32","author":"T Tamura","year":"2012","unstructured":"Tamura T, Yoshida M, Hashizume Y, Sobue G. Lewy body-related \u03b1-synucleinopathy in the spinal cord of cases with incidental Lewy body disease. Neuropathology. 2012;32:13\u201322.","journal-title":"Neuropathology"},{"key":"622_CR156","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.26431","volume":"30","author":"D Berg","year":"2015","unstructured":"Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson\u2019s disease: MDS Criteria for Prodromal PD. Movement Disord. 2015;30:1600\u201311.","journal-title":"Movement Disord"},{"key":"622_CR157","doi-asserted-by":"publisher","unstructured":"Berg D, Borghammer P, Fereshtehnejad S-M, Heinzel S, Horsager J, Schaeffer E, et al. Prodromal Parkinson disease subtypes \u2014 key to understanding heterogeneity. Nat Rev Neurol. 2021;17(6):349-361. https:\/\/doi.org\/10.1038\/s41582-021-00486-9. Epub 2021 Apr 20. PMID: 33879872.","DOI":"10.1038\/s41582-021-00486-9"},{"key":"622_CR158","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/brain\/awz111","volume":"142","author":"S-M Fereshtehnejad","year":"2019","unstructured":"Fereshtehnejad S-M, Yao C, Pelletier A, Montplaisir JY, Gagnon J-F, Postuma RB. Evolution of prodromal Parkinson\u2019s disease and dementia with Lewy bodies: a prospective study. Brain. 2019;142:2051\u201367.","journal-title":"Brain"},{"key":"622_CR159","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1474-4422(14)70287-X","volume":"14","author":"A Schrag","year":"2015","unstructured":"Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson\u2019s disease in primary care: a case-control study. Lancet Neurol. 2015;14:57\u201364.","journal-title":"Lancet Neurol"},{"key":"622_CR160","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/cercor\/bhx137","volume":"28","author":"S Rahayel","year":"2017","unstructured":"Rahayel S, Postuma RB, Montplaisir J, Bedetti C, Brambati S, Carrier J, et al. Abnormal gray matter shape, thickness, and volume in the motor cortico-subcortical loop in idiopathic rapid eye movement sleep behavior disorder: association with clinical and motor features. Cereb Cortex. 2017;28:658\u201371.","journal-title":"Cereb Cortex"},{"key":"622_CR161","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/acn3.50962","volume":"7","author":"TR Barber","year":"2020","unstructured":"Barber TR, Griffanti L, Bradley KM, McGowan DR, Lo C, Mackay CE, et al. Nigrosome 1 imaging in REM sleep behavior disorder and its association with dopaminergic decline. Ann Clin Transl Neur. 2020;7:26\u201335.","journal-title":"Ann Clin Transl Neur"},{"key":"622_CR162","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","volume":"20","author":"A Iranzo","year":"2021","unstructured":"Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, et al. Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol. 2021;20:203\u201312.","journal-title":"Lancet Neurol"},{"key":"622_CR163","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.smrv.2018.09.008","volume":"43","author":"A Galbiati","year":"2019","unstructured":"Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L. The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2019;43:37\u201346.","journal-title":"Sleep Med Rev"},{"key":"622_CR164","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-018-0016-5","volume":"4","author":"Y Dauvilliers","year":"2018","unstructured":"Dauvilliers Y, Schenck CH, Postuma RB, Iranzo A, Luppi P-H, Plazzi G, et al. REM sleep behaviour disorder. Nat Rev Dis Primers. 2018;4:19.","journal-title":"Nat Rev Dis Primers"},{"key":"622_CR165","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.brainres.2014.02.040","volume":"1559","author":"T-Z Chen","year":"2014","unstructured":"Chen T-Z, Xu G-J, Zhou G-A, Wang J-R, Chan P, Du Y-F. Postural sway in idiopathic rapid eye movement sleep behavior disorder: a potential marker of prodromal Parkinson\u2032s disease. Brain Res. 2014;1559:26\u201332.","journal-title":"Brain Res"},{"key":"622_CR166","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.26665","volume":"31","author":"L Alibiglou","year":"2016","unstructured":"Alibiglou L, Videnovic A, Planetta PJ, Vaillancourt DE, MacKinnon CD. Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: a harbinger of freezing of gait? Mov Disord. 2016;31:1711\u20139.","journal-title":"Mov Disord"},{"key":"622_CR167","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1093\/brain\/awp244","volume":"132","author":"RB Postuma","year":"2009","unstructured":"Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson\u2019s disease. Brain. 2009;132:3298\u2013307.","journal-title":"Brain"},{"key":"622_CR168","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/brain\/aws093","volume":"135","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012;135:1860\u201370.","journal-title":"Brain"},{"key":"622_CR169","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/brain\/123.6.1155","volume":"123","author":"I Eisensehr","year":"2000","unstructured":"Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorderComparison with Parkinson\u2019s disease and controls. Brain. 2000;123:1155\u201360.","journal-title":"Brain"},{"key":"622_CR170","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.smrv.2018.04.001","volume":"41","author":"M Bauckneht","year":"2018","unstructured":"Bauckneht M, Chincarini A, Carli FD, Terzaghi M, Morbelli S, Nobili F, et al. Presynaptic dopaminergic neuroimaging in REM sleep behavior disorder: a systematic review and meta-analysis. Sleep Med Rev. 2018;41:266\u201374.","journal-title":"Sleep Med Rev"},{"key":"622_CR171","doi-asserted-by":"publisher","first-page":"17631","DOI":"10.1038\/s41598-020-74495-x","volume":"10","author":"LC Beauchamp","year":"2020","unstructured":"Beauchamp LC, Villemagne VL, Finkelstein DI, Dor\u00e9 V, Bush AI, Barnham KJ, et al. Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism. Sci Rep-uk. 2020;10:17631.","journal-title":"Sci Rep-uk"},{"key":"622_CR172","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/0271678X19828916","volume":"40","author":"Z Huang","year":"2019","unstructured":"Huang Z, Jiang C, Li L, Xu Q, Ge J, Li M, et al. Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder. J Cereb Blood Flow Metab. 2019;40:552\u201362.","journal-title":"J Cereb Blood Flow Metab"},{"key":"622_CR173","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ana.24646","volume":"79","author":"RD Marzi","year":"2016","unstructured":"Marzi RD, Seppi K, H\u00f6gl B, M\u00fcller C, Scherfler C, Stefani A, et al. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol. 2016;79:1026\u201330.","journal-title":"Ann Neurol"},{"key":"622_CR174","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/brain\/aww124","volume":"139","author":"M Rolinski","year":"2016","unstructured":"Rolinski M, Griffanti L, Piccini P, Roussakis AA, Szewczyk-Krolikowski K, Menke RA, et al. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson\u2019s disease. Brain. 2016;139:2224\u201334.","journal-title":"Brain"},{"key":"622_CR175","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.5665\/sleep.3222","volume":"36","author":"TM Ellmore","year":"2013","unstructured":"Ellmore TM, Castriotta RJ, Hendley KL, Aalbers BM, Furr-Stimming E, Hood AJ, et al. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep. 2013;36:1885\u201392.","journal-title":"Sleep"},{"key":"622_CR176","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/brain\/aww006","volume":"139","author":"M Ehrminger","year":"2016","unstructured":"Ehrminger M, Latimier A, Pyatigorskaya N, Garcia-Lorenzo D, Leu-Semenescu S, Vidailhet M, et al. The coeruleus\/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2016;139:1180\u20138.","journal-title":"Brain"},{"key":"622_CR177","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1474-4422(10)70216-7","volume":"9","author":"A Iranzo","year":"2010","unstructured":"Iranzo A, Lome\u00f1a F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2010;9:1070\u20137.","journal-title":"Lancet Neurol"},{"key":"622_CR178","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/mds.22483","volume":"24","author":"H Stockner","year":"2009","unstructured":"Stockner H, Iranzo A, Seppi K, Serradell M, Gschliesser V, Sojer M, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord. 2009;24:1906\u20139.","journal-title":"Mov Disord"},{"key":"622_CR179","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.sleep.2009.12.006","volume":"11","author":"M Iwanami","year":"2010","unstructured":"Iwanami M, Miyamoto T, Miyamoto M, Hirata K, Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med. 2010;11:361\u20135.","journal-title":"Sleep Med"},{"key":"622_CR180","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s10072-012-1164-0","volume":"34","author":"HY Shin","year":"2013","unstructured":"Shin HY, Joo EY, Kim ST, Dhong H-J, Cho JW. Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson\u2019s disease and normal control. Neurol Sci. 2013;34:935\u201340.","journal-title":"Neurol Sci"},{"key":"622_CR181","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/sleep\/33.6.767","volume":"33","author":"MM Unger","year":"2010","unstructured":"Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory Region, and other brain Regions. Sleep. 2010;33:767\u201373.","journal-title":"Sleep"},{"key":"622_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2020.102185","volume":"26","author":"S-A Ahmadi","year":"2020","unstructured":"Ahmadi S-A, B\u00f6tzel K, Levin J, Maiostre J, Klein T, Wein W, et al. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson\u2019s disease: a multi-modal atlas study with transcranial ultrasound and MRI. Neuroimage Clin. 2020;26: 102185.","journal-title":"Neuroimage Clin"},{"key":"622_CR183","doi-asserted-by":"publisher","first-page":"20863","DOI":"10.1038\/srep20863","volume":"6","author":"D-H Li","year":"2016","unstructured":"Li D-H, He Y-C, Liu J, Chen S-D. Diagnostic accuracy of transcranial sonography of the substantia Nigra in Parkinson\u2019s disease: a systematic review and meta-analysis. Sci Rep-uk. 2016;6:20863.","journal-title":"Sci Rep-uk"},{"key":"622_CR184","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.smrv.2016.06.006","volume":"34","author":"J Heller","year":"2017","unstructured":"Heller J, Brcina N, Dogan I, Holtbernd F, Romanzetti S, Schulz JB, et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) \u2013 A systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev. 2017;34:23\u201333.","journal-title":"Sleep Med Rev"},{"key":"622_CR185","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/brain\/awz260","volume":"142","author":"H Wilson","year":"2019","unstructured":"Wilson H, Dervenoulas G, Pagano G, Tyacke RJ, Polychronis S, Myers J, et al. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson\u2019s disease: an in vivo11C-BU99008 PET study. Brain. 2019;142:3116\u201328.","journal-title":"Brain"},{"key":"622_CR186","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s00415-014-7317-8","volume":"261","author":"L Ferini-Strambi","year":"2014","unstructured":"Ferini-Strambi L, Oertel W, Dauvilliers Y, Postuma RB, Marelli S, Iranzo A, et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case\u2013control study. J Neurol. 2014;261:1112\u20138.","journal-title":"J Neurol"},{"key":"622_CR187","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1212\/01.wnl.0000249313.25627.2e","volume":"67","author":"T Miyamoto","year":"2006","unstructured":"Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006;67:2236\u20138.","journal-title":"Neurology"},{"key":"622_CR188","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/mds.25653","volume":"28","author":"EM McDade","year":"2013","unstructured":"McDade EM, Boot BP, Christianson TJH, Pankratz VS, Boeve BF, Ferman TJ, et al. Subtle gait changes in patients with REM sleep behavior disorder. Movement Disord. 2013;28:1847\u201353.","journal-title":"Movement Disord"},{"key":"622_CR189","doi-asserted-by":"publisher","first-page":"677213","DOI":"10.3389\/fneur.2021.677213","volume":"12","author":"G Giannini","year":"2021","unstructured":"Giannini G, Provini F, Cortelli P, Calandra-Buonaura G. REM sleep behaviour disorder in multiple system atrophy: from prodromal to progression of disease. Front Neurol. 2021;12:677213.","journal-title":"Front Neurol"},{"key":"622_CR190","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/mds.28026","volume":"35","author":"C Wilke","year":"2020","unstructured":"Wilke C, Santos MCT, Schulte C, Deuschle C, Scheller D, Verbelen M, et al. Intraindividual neurofilament dynamics in serum mark the conversion to sporadic Parkinson\u2019s disease. Mov Disord. 2020;35:1233\u20138.","journal-title":"Mov Disord"},{"key":"622_CR191","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/mds.20141","volume":"19","author":"U Sommer","year":"2004","unstructured":"Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, et al. Detection of presymptomatic Parkinson\u2019s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord. 2004;19:1196\u2013202.","journal-title":"Mov Disord"},{"key":"622_CR192","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.WNL.0000161874.52302.5D","volume":"64","author":"A Siderowf","year":"2005","unstructured":"Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. &lsqb;99mTc&rsqb;TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology. 2005;64:1716\u201320.","journal-title":"Neurology"},{"key":"622_CR193","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1212\/WNL.0000000000000960","volume":"83","author":"D Jennings","year":"2014","unstructured":"Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Imaging prodromal Parkinson disease. Neurology. 2014;83:1739\u201346.","journal-title":"Neurology"},{"key":"622_CR194","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.24384","volume":"77","author":"R Fern\u00e1ndez-Santiago","year":"2015","unstructured":"Fern\u00e1ndez-Santiago R, Iranzo A, Gaig C, Serradell M, Fern\u00e1ndez M, Tolosa E, et al. MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol. 2015;77:895\u2013901.","journal-title":"Ann Neurol"},{"key":"622_CR195","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-018-0781-5","volume":"17","author":"U Baumgartner","year":"2018","unstructured":"Baumgartner U, Berger F, Gheinani AH, Burgener SS, Monastyrskaya K, Vassella E. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer. Mol Cancer. 2018;17:44.","journal-title":"Mol Cancer"},{"key":"622_CR196","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpsychires.2020.09.006","volume":"131","author":"T Horai","year":"2020","unstructured":"Horai T, Boku S, Okazaki S, Otsuka I, Ratta-apha W, Mouri K, et al. miR-19b is elevated in peripheral blood of schizophrenic patients and attenuates proliferation of hippocampal neural progenitor cells. J Psychiatr Res. 2020;131:102\u20137.","journal-title":"J Psychiatr Res"},{"key":"622_CR197","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/mds.104","volume":"33","author":"AM Smith","year":"2018","unstructured":"Smith AM, Depp C, Ryan BJ, Johnston GI, Alegre-Abarrategui J, Evetts S, et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson\u2019s blood cells. Movement Disord. 2018;33:1580\u201390.","journal-title":"Movement Disord"},{"key":"622_CR198","first-page":"e28032","volume":"6","author":"A Heintz-Buschart","year":"2017","unstructured":"Heintz-Buschart A, Pandey U, Wicke T, Sixel-D\u00f6ring F, Janzen A, Sittig-Wiegand E, et al. The nasal and gut microbiome in Parkinson\u2019s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2017;6:e28032.","journal-title":"Mov Disord"},{"key":"622_CR199","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neur. 2016;3:812\u20138.","journal-title":"Ann Clin Transl Neur"},{"key":"622_CR200","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40478-021-01175-w","volume":"9","author":"C Bargar","year":"2021","unstructured":"Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies. Acta Neuropathol Commun. 2021;9:62.","journal-title":"Acta Neuropathol Commun"},{"key":"622_CR201","doi-asserted-by":"publisher","first-page":"569446","DOI":"10.3389\/fneur.2020.569446","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Yang J, Yuan Y, He Q, Gao Y, Jiang C, et al. Optimization of the detection method for phosphorylated \u03b1-synuclein in Parkinson disease by skin biopsy. Front Neurol. 2020;11:569446.","journal-title":"Front Neurol"},{"key":"622_CR202","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S, Capellari S, Giannini G, Orr\u00f9 CD, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140:49\u201362.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"622_CR203","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","volume":"144","author":"A Stefani","year":"2021","unstructured":"Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C, et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain. 2021;144(4):1118\u201326.","journal-title":"Brain"},{"key":"622_CR204","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011935","author":"V Donadio","year":"2021","unstructured":"Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011935.","journal-title":"Neurology"},{"key":"622_CR205","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrneurol.2012.80","volume":"8","author":"RL Doty","year":"2012","unstructured":"Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8:329\u201339.","journal-title":"Nat Rev Neurol"},{"key":"622_CR206","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ana.21291","volume":"63","author":"GW Ross","year":"2008","unstructured":"Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson\u2019s disease. Ann Neurol. 2008;63:167\u201373.","journal-title":"Ann Neurol"},{"key":"622_CR207","doi-asserted-by":"publisher","first-page":"awz030","DOI":"10.1093\/brain\/awz030","volume":"142","author":"RB Postuma","year":"2019","unstructured":"Postuma RB, Iranzo A, Hu M, H\u00f6gl B, Boeve BF, Manni R, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142:awz030.","journal-title":"Brain"},{"key":"622_CR208","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.24985","volume":"27","author":"D Berg","year":"2012","unstructured":"Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson\u2019s disease: lessons from ongoing studies. Mov Disord. 2012;27:656\u201365.","journal-title":"Mov Disord"},{"key":"622_CR209","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2017.02.017","volume":"38","author":"ME Domell\u00f6f","year":"2017","unstructured":"Domell\u00f6f ME, Lundin K-F, Edstr\u00f6m M, Forsgren L. Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson\u2019s disease. Parkinsonism Relat D. 2017;38:41\u20137.","journal-title":"Parkinsonism Relat D"},{"key":"622_CR210","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00702-019-01996-z","volume":"126","author":"MP Cecchini","year":"2019","unstructured":"Cecchini MP, Federico A, Zanini A, Mantovani E, Masala C, Tinazzi M, et al. Olfaction and taste in Parkinson\u2019s disease: the association with mild cognitive impairment and the single cognitive domain dysfunction. J Neural Transm. 2019;126:585\u201395.","journal-title":"J Neural Transm"},{"key":"622_CR211","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1007\/s00415-020-10048-6","volume":"267","author":"P Marrero-Gonz\u00e1lez","year":"2020","unstructured":"Marrero-Gonz\u00e1lez P, Iranzo A, Bedoya D, Serradell M, Ni\u00f1erola-Baiz\u00e1n A, Perissinotti A, et al. Prodromal Parkinson disease in patients with idiopathic hyposmia. J Neurol. 2020;267:3673\u201382.","journal-title":"J Neurol"},{"key":"622_CR212","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neulet.2009.02.006","volume":"453","author":"L Silveira-Moriyama","year":"2009","unstructured":"Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W, et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett. 2009;453:77\u201380.","journal-title":"Neurosci Lett"},{"key":"622_CR213","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.24962","volume":"27","author":"M Poulopoulos","year":"2012","unstructured":"Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson\u2019s disease. Mov Disord. 2012;27:831\u201342.","journal-title":"Mov Disord"},{"key":"622_CR214","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.21541","volume":"64","author":"RE Burke","year":"2008","unstructured":"Burke RE, Dauer WT, Vonsattel JPG. A critical evaluation of the Braak staging scheme for Parkinson\u2019s disease. Ann Neurol. 2008;64:485\u201391.","journal-title":"Ann Neurol"},{"key":"622_CR215","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-008-0344-8","volume":"115","author":"G Halliday","year":"2008","unstructured":"Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson\u2019s disease. Acta Neuropathol. 2008;115:409\u201315.","journal-title":"Acta Neuropathol"},{"key":"622_CR216","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2990.2007.00923.x","volume":"34","author":"ME Kalaitzakis","year":"2008","unstructured":"Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson\u2019s disease: a critical analysis of \u03b1-synuclein staging. Neuropathol Appl Neurobiol. 2008;34:284\u201395.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"622_CR217","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/emmm.201302475","volume":"5","author":"A Ulusoy","year":"2013","unstructured":"Ulusoy A, Rusconi R, P\u00e9rez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, et al. Caudo-rostral brain spreading of \u03b1-synuclein through vagal connections. Embo Mol Med. 2013;5:1119\u201327.","journal-title":"Embo Mol Med"},{"key":"622_CR218","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-016-1661-y","volume":"133","author":"A Ulusoy","year":"2017","unstructured":"Ulusoy A, Phillips RJ, Helwig M, Klinkenberg M, Powley TL, Monte DAD. Brain-to-stomach transfer of \u03b1-synuclein via vagal preganglionic projections. Acta Neuropathol. 2017;133:381\u201393.","journal-title":"Acta Neuropathol"},{"key":"622_CR219","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/brain\/awaa096","volume":"143","author":"M-L Arotcarena","year":"2020","unstructured":"Arotcarena M-L, Dovero S, Prigent A, Bourdenx M, Camus S, Porras G, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain. 2020;143:1462\u201375.","journal-title":"Brain"},{"key":"622_CR220","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/mds.27138","volume":"33","author":"P Borghammer","year":"2018","unstructured":"Borghammer P. How does parkinson\u2019s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord. 2018;33:48\u201357.","journal-title":"Mov Disord"},{"key":"622_CR221","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen K, Fedorova TD, Hansen AK, Sommerauer M, Otto M, Svendsen KB, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018;17:618\u201328.","journal-title":"Lancet Neurol"},{"key":"622_CR222","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, Andersen KB, Knudsen K, Skj\u00e6rb\u00e6k C, Fedorova TD, Okkels N, et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143:3077\u201388.","journal-title":"Brain"},{"key":"622_CR223","first-page":"1467","volume":"5","author":"WJ Schulz-Schaeffer","year":"2015","unstructured":"Schulz-Schaeffer WJ. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson\u2019s disease? Biomol. 2015;5:1467\u201379.","journal-title":"Biomol"},{"key":"622_CR224","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of Cinpanemab in Early Parkinson\u2019s Disease. New Engl J Med. 2022;387:408\u201320.","journal-title":"New Engl J Med"},{"key":"622_CR225","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. New Engl J Med. 2022;387:421\u201332.","journal-title":"New Engl J Med"},{"key":"622_CR226","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJMe2207681","volume":"387","author":"A Whone","year":"2022","unstructured":"Whone A. Monoclonal antibody therapy in Parkinson\u2019s disease \u2014 The End? New Engl J Med. 2022;387:466\u20137.","journal-title":"New Engl J Med"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-023-00622-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:05:25Z","timestamp":1683885925000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-023-00622-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":226,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1186\/s13024-023-00622-7","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.a.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to publish the manuscript","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that we have no competing interests. J.L. reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent \u201cOral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies\u201d (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent \u201cPharmaceutical Composition and Methods of Use\u201d (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}